ECONSALUT

 REINSURANCE, REPAYMENTS, AND RISK ADJUSTMENT IN INDIVIDUAL HEALTH INSURANCE McGuire, Schillo and Van Cleef provide an additional perspectiv...

 Towards a theory of ecosystems In this article , you'll find a good description of the features of a business ecosystem. Unfortunately,...

 What Gene Editing Can Do for Humankind? In WSJ you'll find a good op-ed by Walter Isaacson,  After millions of centuries during which e...

 Design of financial incentives and payment schemes in healthcare systems: A review

 On the Much Used (and Abused) Word "Value" in Healthcare  A must read speech by Uwe Reinhardt (RIP). Selected statements: Now, wh...

 In the wake of the pandemic. Preparing for Long COVID     Policy responses need to take account of the complexity of Long COVID and how wha...

 Regulating the unknown. A guide to regulating genomics for health policy-makers In the absence of appropriate regulation and guidance, the ...

 Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach Cost-eff...

 Building on value-based health care A reminder: Within the context of solidarity-based European health care systems and the mounting concer...

  A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder D...

 Distributional Cost-Effectiveness Analysis. Quantifying Health Equity Impacts and Trade-Offs Distributional Cost-Effectiveness Analysis Com...

  Covid-19 and the business of vaccines The FT explains the business models behind vaccines and asks if the Covid-19 pandemic will fundament...

 Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs In US: The number of ultra-expensive drugs and Medicare beneficiaries taki...

  CRISPR People. The Science and Ethics of Editing Humans A book on the ethics of CRISPR, without a clear prescription, only a review of He ...